Inhibition of Platelet Glycoprotein Ib and Its Antithrombotic Potential

Author(s): Karen Vanhoorelbeke, Hans Ulrichts, Gerlinde Van de Walle, Alexandre Fontayne, Hans Deckmyn

Journal Name: Current Pharmaceutical Design

Volume 13 , Issue 26 , 2007

Become EABM
Become Reviewer

Abstract:

The platelet receptor glycoprotein (GP)Ib-IX-V complex plays a dominant role in the first steps of platelet adhesion and arterial thrombus formation. Through its interaction with the multimeric plasma protein von Willebrand factor (VWF), which is bound to the damaged subendothelial structures, GPIb-IX-V tethers the platelets from the flowing blood thereby slowing them down. This step is a prerequisite for the collagen receptors to participate in firm adhesion resulting in the formation of a first platelet layer which is the basis for further thrombus formation. Recently, other ligands for GPIb-IX-V besides the extensively studied VWF have been identified, such as : α-thrombin, coagulation factor XII (FXII), high molecular weight kininogen (HMWK), factor XI (FXI), integrin Mac-1 and P-selectin. In this review, the interaction of GPIb-IX-V with its different ligands is described and the anticipated or demonstrated in vivo effects are discussed.

Keywords: Glycoprotein Ib, platelets, antithrombotic agents

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 26
Year: 2007
Page: [2684 - 2697]
Pages: 14
DOI: 10.2174/138161207781662867
Price: $65

Article Metrics

PDF: 11